Personal Statement
Joe Sacco is a Reader and Honorary Consultant Medical Oncologist at the University of Liverpool and The Clatterbridge Cancer Centre respectively. He graduated in Medicine and Surgery from the University of Zimbabwe in 1999, and holds a PhD from the University of Liverpool. His clinical specialities are melanoma, early phase trials and H&N cancer, with a subspecialist focus on uveal melanoma (UM); a rare cancer which frequently metastasises and for which there remain few treatment options.

Research Overview
Joe Sacco is a clinical academic with research interests spanning basic, translational and clinical domains. Joe has led or contributed to a broad portfolio of clinical trials, including key trials in clinical development of tebentafusp, as well as the FOCUS clinical trial investigating percutaneous perfusion with melphalan; the only two therapeutic options to be licenced for metastatic uveal melanoma. He is UK lead for the OMNI study, an international natural history study of uveal melanoma as well as UK lead for the UM international rare cancer initiative. His basic science interests include BAP1 signalling and targeting, and the development of a model of the tumour microenvironment of UM metastatic to the liver.